Oral Health CRC parties, the University of Melbourne and CSL, together with Brandon Capital have established a spinout, Denetric Pty Ltd, to develop and commercialise the research outputs of the Oral Health CRC’s Porphyromonas gingivalis (Pg) vaccine research program.
The Pg vaccine research program, led by Laureate Professor Eric Reynolds AO from the University of Melbourne is a long- running collaboration between the University of Melbourne and CSL Ltd that began in the 1990s and progressed under the Victorian State Government-funded Victorian Centre for Oral Health Science (VCOHS), the CRC for Oral Health Science and the Oral Health CRC with Australian Government funding through the CRC Program in the Department of Industry Innovation and Science.
Denteric will receive AU$14 million capital investment from the Medical Research Commercialisation Fund’s (MRCF) Biomedical Translation Fund, a Commonwealth-backed fund managed by Brandon Capital Partners, CSL Ltd., Australia’s largest biotechnology company, and the University of Melbourne.
Periodontal gum disease is a debilitating condition that affects a third of all adults globally, however no therapies or treatments exist, and it remains a major unmet medical need.
Denteric is looking to commence its first clinical trial in humans in the next two to three years.